The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

MLA

Leonardo Provenzano, et al. “The Pan-Immune-Inflammation Value Is Associated with Clinical Outcomes in Patients with Advanced TNBC Treated with First-Line, Platinum-Based Chemotherapy: An Institutional Retrospective Analysis.” Therapeutic Advances in Medical Oncology, vol. 15, Apr. 2023. EBSCOhost, https://doi.org/10.1177/17588359231165978.

APA

Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, & Giovanni Fucà. (2023). The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. Therapeutic Advances in Medical Oncology, 15. https://doi.org/10.1177/17588359231165978

Chicago

Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, et al. 2023. “The Pan-Immune-Inflammation Value Is Associated with Clinical Outcomes in Patients with Advanced TNBC Treated with First-Line, Platinum-Based Chemotherapy: An Institutional Retrospective Analysis.” Therapeutic Advances in Medical Oncology 15 (April). doi:10.1177/17588359231165978.